JAK-2V617F Mutation in Acute Leukemia (South Egypt Experience)

References (29)

1. 1 A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [DOI]
2. 2 A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders [DOI]
3. 3 Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [DOI]
4. 4 Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis [DOI]
5. 5 The STATs of cancer — new molecular targets come of age [DOI]
6. 6 Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [DOI]
7. 7 Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders [DOI]
8. 8 A TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human Leukemia [DOI]
9. 9 Fusion of TEL, the ETS-Variant Gene 6 (ETV6), to the Receptor-Associated Kinase JAK2 as a Result of t(9; 12) in a Lymphoid and t(9; 15; 12) in a Myeloid Leukemia [DOI]
10. 10 The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes [DOI]
11. 11 The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia [DOI]
12. 12 JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome–negative CML, and megakaryocytic leukemia [DOI]
13. 13 What's going on 造血器腫瘍 A gain-of-function mutation of JAK2 in myeloproliferative disorders. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. N Engl J Med. 2005; 352: 1779-90. PMID:15858187.--慢性骨髄増殖性疾患においてJAK2遺伝子の変異が高頻度にみられることを示した論文
14. 14 Series Introduction: JAK-STAT signaling in human disease [DOI]
15. 15 Series Introduction: JAK-STAT signaling in human disease [DOI]
16. 16 The JAK2 V617F mutation in de novo acute myelogenous leukemias [DOI]
17. 17 JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained [DOI]
18. 18 TEL-JAK2 transgenic mice develop T-cell leukemia [DOI]
19. 19 TEL-JAK2 transgenic mice develop T-cell leukemia [DOI]
20. 20 JAK/STAT signaling pathways and cancer. Janus kinases/signal transducers and activators of transcription.
21. 21 Some Speculations on the Myeloproliferative Syndromes
22. 22 Fusion of TEL, the ETS-Variant Gene 6 (ETV6), to the Receptor-Associated Kinase JAK2 as a Result of t(9; 12) in a Lymphoid and t(9; 15; 12) in a Myeloid Leukemia [DOI]
23. 23 Jak2 Tyrosine Kinase: A True Jak of All Trades? [DOI]
24. 24 JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia [DOI]
25. 25 JAK Protein Kinase Inhibitors [DOI]
26. 26 The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia [DOI]
27. 27 Flow cytometric measurement of phosphorylated STAT5 in AML: lack of specific association with FLT3 internal tandem duplications [DOI]
28. 28 The Janus Kinase 2 (JAK2) V617F mutation in hematological malignancies in México.
29. 29 Editorial: Some Speculations on the Myeloproliferative Syndromes [DOI]

Cited by 0

No indexed citations yet.

Related research

• Haemato-biochemical Alterations and Significance of Prognostic Indicators in Dogs with Canine Parvoviral Infection — shares topic coverage
• Outpatient Management of Acute Leukemia: A Systematic Review and Meta Analysis — shares topic coverage
• Aberrant Expression of CD19 in Early T-cell Precursor Lymphoblastic Leukemia- A Diagnostic Challenge — shares topic coverage
• Place of Bone Marrow Transplantation for Patients with Hematology Malignancy in Abidjan, Côte d’Ivoire: A Retrospective Cross-Sectional Study — shares topic coverage
• Spectrum of Complications in Patients of Acute Leukemia- A Regional Study from Pgims, Rohtak — shares topic coverage